Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.04 SGD
Change Today 0.00 / 0.00%
Volume 0.0
PHM On Other Exchanges
Symbol
Exchange
Singapore
As of 11:44 PM 08/24/15 All times are local (Market data is delayed by at least 15 minutes).

pharmesis international ltd (PHM) Snapshot

Open
$0.04
Previous Close
$0.35
Day High
$0.04
Day Low
$0.04
52 Week High
06/3/15 - $0.57
52 Week Low
08/24/15 - $0.21
Market Cap
7.0M
Average Volume 10 Days
22.0
EPS TTM
$-0.14
Shares Outstanding
20.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMESIS INTERNATIONAL LTD (PHM)

Related News

No related news articles were found.

pharmesis international ltd (PHM) Related Businessweek News

No Related Businessweek News Found

pharmesis international ltd (PHM) Details

Pharmesis International Ltd., an investment holding company, develops, manufactures, and sells western medicines, and traditional Chinese medicines (TCM) in the People’s Republic of China. It operates through three segments: Western Drugs, TCM Formulated Drugs, and Distribution. The company’s pharmaceutical products include prescribed products and over-the-counter drugs. It offers pharmaceutical products in the form of tablets, granules, pills, etc. The company offers Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Gansu for use in treating acute and chronic hepatitis; Er Ding Granules for the treatment of jaundice, as well as clears heat toxin; and Xiao Shi Jian Pi for use in treating flatus, inappetency, dyspepsy, and spleen weakness. It also provides ShuLingHou tablets used in the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness; Lianpu Shuangqing for use in treating acute inflammation, such as dysentery and intestinal infection; Xiaoluotong Jiaonang for the treatment of rheumatoid arthritis and other rheumatic diseases; and Afenka for use in treating of migraine, relieves pain from headache, cold, nasosinusitis, muscle pain, menstrual pain, toothache, and arthritis. The company markets its western drugs under the Kinna brand name; and TCM formulated drugs under the Longlife brand name to hospitals. In addition, it engages in the wholesale of chemical drugs, biological raw products, TCM products, antibiotics, and antibiotics agents. Pharmesis International Ltd. was founded in 1996 and is headquartered in Chengdu, the People’s Republic of China.

Founded in 1996

pharmesis international ltd (PHM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $214.0K
Compensation as of Fiscal Year 2014.

pharmesis international ltd (PHM) Key Developments

Pharmesis International Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Pharmesis International Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of RMB 16,012,000 against RMB 14,552,000 a year ago. Profit from operations was RMB 817,000 against loss from operations of RMB 1,041,000 a year ago. Profit before tax was RMB 593,000 against loss before tax of RMB 356,000 a year ago. Profit for the period attributable to equity holders of the company was RMB 150,000 or 0.07 cents diluted per share against loss for the period attributable to equity holders of the company of RMB 119,000 or 0.06 cents diluted per share a year ago. Net cash flows used in operating activities were RMB 3,121,000 against net cash flows from operating activities of RMB 2,738,000 a year ago. Acquisition of property, plant and equipment was RMB 1,398,000 against RMB 185,000 a year ago. For the six months, the company reported revenue of RMB 30,050,000 against RMB 27,986,000 a year ago. Profit from operations was RMB 80,000 against loss from operations of RMB 2,818,000 a year ago. Profit before tax was RMB 744,000 against loss before tax of RMB 1,482,000 a year ago. Profit for the period attributable to equity holders of the company was RMB 446,000 or 0.22 cents diluted per share against loss for the period attributable to equity holders of the company of RMB 578,000 or 0.29 cents diluted per share a year ago. Net cash flows used in operating activities were RMB 1,652,000 against net cash flows from operating activities of RMB 3,610,000 a year ago. Acquisition of property, plant and equipment was RMB 1,402,000 against RMB 268,000 a year ago. Group net asset value per ordinary share as on June 30, 2015 was 43.88 cents against 43.66 cents as on June 30, 2014. Company net asset value per ordinary share as on June 30, 2015 was 27.87 cents against 28.81 cents as on June 30, 2014.

Pharmesis International Ltd. to Report Q2, 2015 Results on Aug 14, 2015

Pharmesis International Ltd. announced that they will report Q2, 2015 results on Aug 14, 2015

Pharmesis International Ltd., Special/Extraordinary Shareholders Meeting, Aug 20, 2015

Pharmesis International Ltd., Special/Extraordinary Shareholders Meeting, Aug 20, 2015., at 14:30 Singapore Standard Time. Location: 5 Kallang Sector, #03-02. Agenda: To consider the proposed adoption of the new IPT general mandate; and to consider proposed consolidation of every 10 existing issued ordinary shares in the capital of the company held by shareholders of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PHM:SP $0.04 SGD 0.00

PHM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PHM.
View Industry Companies
 

Industry Analysis

PHM

Industry Average

Valuation PHM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.5x
Price/Book 0.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMESIS INTERNATIONAL LTD, please visit www.pharmesis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.